Skip to main content
REVB logo

REVB · Revelation Biosciences, Inc. · Executive Compensation

Track REVB — free
$3.71 +0.02 (+0.54%)
Market Cap
$2.52M
Shares
683,442
Volume · Nov 20 1858 Avg daily vol (23 sessions) 20.32K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

No Compensation Data

No Summary Compensation Table has been imported from this company's proxy statements yet.

Executive changes

Person Change Filed
Chester S. Zygmont, III Appointed 2026-06-24
James Rolke Appointed 2026-06-24
Jennifer Carver Already on the board
Since at least 2020: re-election or new board role
2026-06-24
George Tidmarsh, M.D., Ph.D.
“The resignation of Dr. Tidmarsh was not a result of any disagreements with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2025-05-28
Lakhmir Chawla M.D. Appointed 2023-10-02
Curt LaBelle, M.D.
“The resignation of Dr. LaBelle was not a result of any disagreements with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2023-10-02
Andreas Typaldos Resigned 2022-01-14
Sean Fitzpatrick Resigned 2022-01-14
Barry Dennis Resigned 2022-01-14
William Carson Resigned 2022-01-14
Anthony Hayes Resigned 2022-01-14
Robert Nicholson Resigned 2022-01-14
Andreas Typaldos Resigned 2022-01-14
David Dobkin Resigned 2022-01-14
Curt LaBelle Appointed 2022-01-14
Jess Roper Appointed 2022-01-14
Jennifer Carver Appointed 2022-01-14
James Rolke Appointed 2022-01-14
George F. Tidmarsh Appointed 2022-01-14

Leadership

Key facts CIK 1810560 CUSIP 76135L887 13F (30d) 16 filings 14 filers Visit website Investor relations